When to Use Stock QC, Custom QC, or Build Your Own: A Decision Framework

Laboratories generally have three options when sourcing quality control materials: stock QC purchased from a third-party manufacturer, custom laboratory quality controls formulated to the lab’s specific panel, or in-house QC prepared internally. Most labs use some combination of the three. The harder question is when each option is the right fit, and the answer depends on six factors that are easy to weigh poorly without experience: analyte coverage, lot-to-lot stability, regulatory documentation, internal resourcing, turnaround time, and true total cost.

This decision plays out in laboratories every week, usually without the benefit of a written framework. What follows is one.

At UTAK, we have spent more than five decades helping laboratories work through exactly this decision. Over that time we have seen labs swing in both directions: from in-house preparation back to third-party QC after underestimating the hidden labor, and from purchased stock controls to Purpose Built programs after discovering that off-the-shelf panels could not keep up with their casework. The decision is rarely about which option is “best” in the abstract. It is about which trade-offs your laboratory can absorb, and which ones become operational pain points six months down the road.

The Three Paths

Each option has a specific role:

  • Stock QC: Pre-formulated materials with defined analyte panels and concentrations, supplied with certificates of analysis. Best suited for routine, well-characterized assays.
  • Purpose Built QC: Custom laboratory quality controls formulated to a lab’s exact analyte panel, concentrations, and matrix specifications by a third-party manufacturer. Best suited for emerging compounds, specialized panels, or unique testing requirements.
  • In-House QC: Materials prepared internally by spiking analytical standards into matrix. Best suited for situations where commercial options do not exist, or where the laboratory has dedicated QC manufacturing infrastructure.

Six Decision Factors

1. Analyte availability and panel coverage. Map your panel against what is commercially available. Stock QC works well when your analyte list overlaps substantially with established panels. The moment you are testing for emerging compounds (nitazenes, designer benzodiazepines, recent fentanyl analogues, novel psychoactive substances), commercial stock options become limited. This is where Purpose Built QC tends to enter the conversation.

2. Lot-to-lot stability needs. Producing a single lot of QC material is manageable for an experienced chemist. Producing successive lots that perform identically, lot after lot, year after year, is a different operational challenge. It requires standardized protocols, validated source materials, statistical infrastructure for comparing lots to historical performance, and documentation that holds up under audit.

3. Regulatory documentation expectations. CLIA, CAP, ISO 15189:2022, and SOFT all expect QC materials to be supported by documented stability, traceability, and characterization. For commercially manufactured QC, this documentation is supplied with the product. For in-house preparation, the laboratory generates and maintains it: stability studies, certificate-equivalent records, traceability of source materials, and storage validation. Auditors increasingly examine that documentation with the same rigor they apply to method validation.

4. Internal resourcing and expertise. Who in your laboratory has the bandwidth to prepare, characterize, document, and maintain QC materials? In our experience, the chemist hours required for in-house QC are routinely underestimated. The math looks favorable when only the cost of analytical standards is counted. It looks different once you add senior chemist time, documentation overhead, and the periodic stability re-evaluation that audit-ready programs require.

5. Turnaround time. Stock QC ships from inventory. Purpose Built QC requires a development conversation, formulation, and characterization, with timelines that vary by complexity. In-house preparation is fast once your program is established, but slow if you are building the infrastructure for the first time. The right comparison is not a single-batch turnaround; it is the time required to have audit-ready, lot-comparable QC available on an ongoing basis.

6. Budget (true total cost). Per-vial cost comparisons are misleading without a full picture of program cost. For in-house QC, that means analytical standards, matrix sourcing, chemist hours, documentation maintenance, and stability testing. For purchased QC, it means unit cost, shipping, and (for Purpose Built programs) any one-time development charges. We have seen labs run both numbers carefully and arrive at conclusions in both directions. For labs that want that full picture without building the model by hand, REALx runs the true-total-cost comparison across sourcing paths.

What Each Path’s Advocates Tend to Underestimate

This is where the decision often gets made on incomplete information.

What DIY-leaning laboratories tend to underestimate:

  • Chemist hours: The labor required to prepare, characterize, and document QC materials for ongoing use, not just a single working batch.
  • Lot-to-lot variability: The statistical infrastructure required to verify that successive lots perform comparably, and the troubleshooting cost when they do not.
  • Regulatory documentation: The audit-ready paper trail that supports in-house QC under modern accreditation expectations.
  • Stability characterization: Real stability data takes months to generate, and “we have used this for years without a problem” is no longer audit-defensible.

What purchased-QC laboratories tend to underestimate:

  • Purpose Built panel flexibility: Many labs assume Purpose Built QC is reserved for niche cases. In practice, custom programs can match a laboratory’s exact panel composition, concentrations, and matrix, often producing better casework alignment than any stock panel.
  • Established statistical infrastructure: Manufacturers with mature QC programs run lot-to-lot comparison statistics, stability monitoring, and characterization studies as routine operations. Labs using purchased QC inherit this infrastructure without building it.
  • Emerging compound coverage: Purpose Built programs can move with the casework. Labs sometimes default to stock QC because it is familiar, when a Purpose Built panel would solve the panel-gap problem they are working around.

For a deeper comparison of preparing QC internally versus working with a third-party manufacturer, our Making Your Own QC vs Third-Party Materials post walks through the practical considerations in more detail. Our In-House Manufacturing post details what a mature QC manufacturing program actually involves on the production side.

When Each Path Makes Sense

  • Stock QC fits when your panel substantially overlaps with established commercial panels, your concentration levels align with available stock products, and your analyte list is stable.
  • Purpose Built QC fits when your panel includes emerging or specialized analytes, your composition or concentrations differ from stock options, you want to consolidate multiple stock products into a single matched control, or you need Purpose Built QC that follows your casework.
  • In-house preparation fits when commercial options genuinely do not exist, your laboratory has dedicated QC manufacturing infrastructure and personnel, and your volume and panel are stable enough to justify the documentation and maintenance overhead.

Key Takeaway: QC Sourcing Decision Checklist

Use this checklist to evaluate your current QC sourcing path:

☐  Panel coverage assessed: Current and planned analyte list mapped against available stock options.

☐  Documentation requirements understood: Accreditation expectations identified for QC documentation in your testing program.

☐  True program cost calculated: Includes chemist hours, documentation, stability work, and infrastructure, not just unit cost.

☐  Lot-to-lot infrastructure evaluated: Established how comparability will be verified and maintained.

☐  Turnaround expectations defined: Aligned with method development and validation timelines.

☐  Conversion triggers identified: Conditions defined that would prompt revisiting the decision (panel expansion, audit findings, staffing changes).

Frequently Asked Questions

When should a laboratory move from stock QC to Purpose Built QC?

The most common trigger is panel composition. When your testing panel diverges meaningfully from available stock products, whether through emerging compound additions, concentration mismatches, or matrix requirements, a custom program often becomes the more efficient path. Other common triggers include consolidating multiple stock products into a single matched control and aligning QC concentrations with actual casework levels.

Is in-house QC ever the right answer?

Yes, in specific situations. When commercial QC genuinely does not exist for an analyte, when your laboratory has dedicated QC manufacturing infrastructure, or when your volume and panel are stable enough to justify the documentation and maintenance burden. The decision typically goes wrong when laboratories underestimate the chemist hours and documentation work required for ongoing operation.

What documentation should a third-party QC manufacturer provide?

At minimum: certificates of analysis with assigned target values and acceptable ranges, lot-specific stability data, traceability information for source materials, and storage and handling guidance. For custom quality control programs, design documentation describing the formulation rationale and characterization is also reasonable to expect.

Revisiting Sourcing Decisions as Your Panel Evolves

This decision is more nuanced than a per-vial cost comparison suggests, and the right answer is not always permanent. Laboratory needs evolve; what made sense for a stable panel three years ago may no longer fit a panel that has expanded to address current casework. We have worked with laboratories on every side of this question, including those who moved to in-house preparation and later reconsidered after the documentation and lot-to-lot infrastructure work added up.

If you are working through this decision, our technical team has had this conversation many times across hundreds of laboratory implementations. Sometimes a 30-minute call with people who have seen the trade-offs play out can shortcut weeks of internal deliberation, or you can run your own numbers first with REALx. Reach out at welovecontrol@utak.com or call 888.882.5522 today.

References

1. Clinical and Laboratory Standards Institute. CLSI C24-Ed4: Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions. CLSI; 2016.

2. International Organization for Standardization. ISO 15189:2022 Medical laboratories: Requirements for quality and competence. ISO; 2022.

3. College of American Pathologists. Laboratory Accreditation Program. Accessed 2026. 4. AAFS Academy Standards Board. ANSI/ASB Standard 054: Standard for a Quality Control Program in Forensic Toxicology Laboratories, First Edition. AAFS; 2021.

Similar Post